Emerson Clinical Research Institute | Kennedy Street NW, Washington

Research site

(Unclaimed)

Location

508 Kennedy Street NW Suite 306, Washington, District of Columbia, United States of America

Site insights

Top conditions

Top treatments

MK-0616

MK-7240

fezolinetant

Tulisokibart

MK-4482

MK-7240-001

Molnupiravir

Tolperisone

Ibuzatrelvir

Pimodivir

Parent organization

This site is a part of Emerson Clinical Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 27 total trials

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation...

Enrolling

Type 2 Diabetes

Drug: Dulaglutide

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia....

Active, not recruiting

Hypercholesterolemia

Familial Hypercholesterolemia

Drug: Enlicitide Decanoate

Drug: Placebo

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study...

Enrolling

Ulcerative Colitis

Drug: IV Placebo

Drug: SC Placebo

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's diseas...

Enrolling

Crohn's Disease

Other: SC Placebo

Drug: IV Tulisokibart

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema (ELEVATUM)

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Active, not recruiting

Diabetic Macular Edema

Drug: Faricimab

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in t...

Enrolling

COVID-19 SARS-CoV-2 Infection

Drug: placebo

Drug: ibuzatrelvir

Status recently updated

A Study to Learn About How a New Pneumococcal Vaccine Works in Children

The purpose of this study is to learn about the safety, tolerability and immune effects of a pneumococcal vaccine in toddlers.Participants will take...

Enrolling

Active, not recruiting

Pneumococcal Disease

Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)

Biological: PG4

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called varian...

Enrolling

COVID-19

SARS-CoV-2 Virus

Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose

Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling

Arteriosclerosis

Hypercholesterolaemia

Drug: Placebo

Drug: Enlicitide Decanoate

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed...

Enrolling

Hypercholesterolemia

Drug: Enlicitide Decanoate

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg